Results 191 to 200 of about 377,702 (260)

BRAF Mutation Affects Intratumor Heterogeneity in Papillary Thyroid Carcinoma. [PDF]

Anal Cell Pathol (Amst)
Feng YE, Wang CJ.
europepmc   +1 more source

Spatiotemporal dynamics of β‐arrestin‐mediated Src activation in 5‐HT7 receptor signaling pathway

The FEBS Journal, EarlyView.
GPCRs induce distinct cellular responses via G protein‐ or β‐arrestin‐mediated signaling pathways. This study revealed that β‐arrestin‐biased 5‐HT7R ligand induces slow, sustained Src activation, contrasting with transient G protein‐mediated activation.
Hyunbin Kim, Yong Woo Lee, Huimin Lee, Eunseo Park, Jieon Lee, Hae Nim Lee, Kyeong‐Man Kim, Hyunah Choo, Jihye Seong   +8 more
wiley   +1 more source

Synergistic target network construction and dynamic simulation analysis based on a prospective systems pharmacology strategy. [PDF]

Medicine (Baltimore)
Li H, Zheng Z, Zhen G, Tang K, Fang H, Wang J, Liu X, Zhu D.   +7 more
europepmc   +1 more source

ADAM17 and its proteolytic targets in disease pathogenesis

The FEBS Journal, EarlyView.
ADAM17 as a multifunctional sheddase with contrasting roles across inflammatory, metabolic, cardiovascular, and neoplastic diseases. Through regulated activation by iRhom, iTAP/FRMD8, and tetraspanins, ADAM17 cleaves diverse membrane ligands and receptors, thereby promoting inflammation, fibrosis, obesity, insulin resistance, and tumor progression ...
Abdulbasit Amin, Marina Badenes
wiley   +1 more source

Exploring the Role of the MAPK Signalling Pathway in Dog Immunity: From Cancer to Parasitic Diseases. [PDF]

Parasite Immunol
Ribeiro FN, Morgado FN, Porrozzi R.
europepmc   +1 more source

From hepatic to hematopoietic: LRH‐1's expanding cellular repertoire to the immune system

The FEBS Journal, EarlyView.
The nuclear receptor LRH‐1 is a well‐characterized regulator of endodermal tissue. Yet, increasing evidence indicates that LRH‐1, although expressed at low levels, is also a critical regulator of the hematopoietic system. LRH‐1 regulates the immune system by contributing to immune cell‐specific functions.
Lukas Meisinger, Alice Wiedmann, Rayan Hassan M. Elshikhidriss, Thomas Brunner   +3 more
wiley   +1 more source

Targeting "undruggable" cancer proteins: pharmacological challenges and emerging strategies. [PDF]

Transl Cancer Res
Coelho-Silva JL, Parducci NS, Carvalho MFL, Vahedian V, Lima K, de Almeida BO, Machado-Neto JA.   +6 more
europepmc   +1 more source

Intrahepatic Cholangiocarcinoma: Epidemiological Trends, Risk Factors, Diagnostic Challenges, and Advances in Personalized Therapy—A Comprehensive Review

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Intrahepatic cholangiocarcinoma (iCCA) ranks as the second most common primary liver cancer, compared to about 20% of cases. Its global incidence has climbed over the past four decades, yet early detection remains indefinable due to its asymptomatic nature. Five‐year survival rate of approximately is under 10%.
Yaqoob Muhammad, YuZhu Jin, Kai Luo, He Bai, Xudong Zhang, Xu Sun, Zahoor Maheen, Ali Tanveer, Saeed Muddasar Muhammad, Jialin Qu, Guixin Zhang   +10 more
wiley   +1 more source

Extrachromosomal DNA in Solid Tumors-Landscape, Immune Effects, and Resistance to Targeted Therapy. [PDF]

Oncol Res
Badran O, Attarya S.
europepmc   +1 more source

Immune Evasion of Helicobacter pylori and Extra‐Gastric Cancer Risk

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Helicobacter pylori (H. pylori) is a group 1 gastric carcinogen that plays a significant role in extra‐gastric digestive system cancers. H. pylori disrupts host cell homeostasis through expression of virulence factors leading to immune evasion as well as persistent gastric mucosal colonization. H. pylori infection has been shown to play a role
Evren Doruk Engin, Ayse Basak Engin, Atilla Engin   +2 more
wiley   +1 more source